NCT06132867View on ClinicalTrials.gov

A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as a Solution Versus When Swallowed as a Tablet in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 20, 2023

Primary Completion Date

February 17, 2024

Study Completion Date

February 17, 2024

Conditions
Healthy Volunteers
Interventions
DRUG

Brigatinib

Brigatinib oral solution

DRUG

Brigatinib

Brigatinib tablet

Trial Locations (1)

85283

Celerion, Inc., Tempe

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY